The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Business
  • Construction
  • Entertainment
  • Legal
  • Sports

Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
The PennZone/10216335

Trending...
  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs
  • School Dental Screening Programs Conducted in Dubai
  • New Luxury Single Family Homes From $976,990 in Manalapan
Beneficience Com Announces Dr John Burd, Renowned Dr John Burd Lysulin© Dr Burd Wonder Spray Skin Rescue 8oz Skin Rescue Lysulin© Products Beneficience.com Legacy PR
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.

SAN DIEGO - PennZone -- About John Burd, PhD:

Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc.  In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes.   The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications.  In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.

Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.  In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million.  In 2020 DexCom had a market cap of over $40 billion.  From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.

Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market.  LXN was sold to Johnson and Johnson in 2000.

More on The PennZone
  • Justice Advisory Group Expands Federal Sentencing, Prison Preparation and Reentry Support Services
  • Advancing High-Potential Nevada Critical Minerals Portfolio as Major Drill Program Nears Assay Results: Glenstar Minerals: Stock Symbol: GSTRF
  • Allstream Energy Partners to Host 6th Executive Networking After 2026 Energy Projects Conference
  • CAPHRA: Australia and Thailand show nicotine prohibition fuels illicit markets
  • Custom Disposables - Wholesale Packaging Solutions for restaurants, food chains, and food distributors

Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance.  MAST Immunosystems was purchased by Hitachi Chemical in 1997.  Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).

Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products.  He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.  In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOHN F. BURD, Ph.D.

Founder & CEO Lysulin, Inc and Wonder Spray, llc.

More on The PennZone
  • California Security Glass is an affordable bulletproof glass installation company in LA serving a variety of neighboring cities
  • Allstream Energy Partners Announce Media Partnership with the 2026 EPC Show - The Energy Projects Conference
  • STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
  • West Virginia Leaders Announce Support for Election Integrity Network's Model Election Laws Handbook
  • CCHR Condemns Behavioral Treatment After FDA's Missed Deadline to Ban Shock Device

4930 Bradshaw Court, San Diego, CA  92130
Phone: 619-992-2873

Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)

Learn more about Dr. Burd's products below...

Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8



Lysulin video:  https://www.youtube.com/watch?v=PK3CkMty6RE



Running A1c test: https://tinyurl.com/y379jbla

Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos

Follow Burd's PR News at http://Beneficience.com

MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd

Contact
Dr. Tracey Bond, MPRL
Certified Publicist of Record
for John Burd, PhD
***@beneficience.com


Source: Beneficience.com Legacy PR
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Mr. Hospital Bed Showcases the Best Hospital Bed and Air Mattress for Bed Sores for 2026
  • Traian TKD Tractari Auto Iasi: cum transporti legal la RAR o masina fara numere sau cu ITP expirat
  • Mike Williams Golf Center Now Open at Georgia's Lanier Islands Resort
  • Appliance EMT Launches June "Summer Rescue" Promotion
  • New Luxury Single Family Homes From $976,990 in Manalapan
  • Longevityresearch.ca Unveils a Unique Bayesian Causal Atlas; Saves up to 7.9 life years/patient
  • Grane Rx, a National Pharmacy Partner to PACE Programs, Names Scott Sosso President
  • K2 Integrity Acquires RiskFront AI to Deliver AI Automation for Financial Crime Compliance and Risk Operations
  • HousingWire acquires Keeping Current Matters, putting local market data into the tools agents use to win listings
  • KIDZONET & Ocean Telecom Launch UK First eSIM Child Protection — EasySim AI Safe SIM Cards
  • School Dental Screening Programs Conducted in Dubai
  • British Brand Daniel Mason™ Expands Premium Braided Leather Belt Collection Internationally
  • Looking for expert pool tiling in Gold Coast? Call Avid Tiling
  • Hosted Network Powers National Growth with netElastic vBNG, CGNAT and netVision
  • Individual Entrepreneur of Annville, PA, Acquires Mosquito Joe of Lancaster, PA
  • Super Lawyers Recognizes Inman & Tourgee Attorneys Mark Tourgee and Jacob Rinn
  • PropAccount.com Launches PropGenie, the First Branding Studio Built for Prop Firm Operators
  • Rushing Headlong: Health IT's Legacy and the Road to Responsible AI is named 2025 Foreword INDIES Book of the Year Awards Winner
  • The Problem With AI Isn't Compute. It's Memory
  • Golden Visa Countries Outpace Eurozone Growth Over Eight Years, New La Vida Analysis Finds

Popular on PennZone

  • New Home of the Month: Spacious Luxury Meets Modern Design in The Bristol at Heritage at Manalapan - 166
  • Love Must Be the Guide: Live Good Shares a Message of Humanity, Compassion and Hope
  • Calvetta Phair, CEO America's Workforce Solution, LLC Assessed "Awardable" for Department of War work in the CDAO's Tradewinds Solutions Marketplace
  • Thou Shalt not Commit Adultery Lifetime Movie Discussion
  • Lansdowne Photographer Steven Weisz Selected for Philadelphia City Hall Exhibition
  • AI Is Closing the Gap Between Offshore Virtual Assistants and Onshore Staff
  • SteelTree Announces Launch of Its Operational Decision Intelligence Service
  • Joseph Nybyk (AKA Joseph Neibich) Guests On Octopus TV
  • Tennessee Laws Lead with Psychotropic Drug Testing in Mass Shooting Cases and Comprehensive Reporting: CCHR Urges Nationwide Adoption
  • Autism Podcast Helps Parents Understand Why Behavior Is Communication, Not Defiance

Similar on PennZone

  • purelyIV Expands Mobile IV Therapy to Jackson, MI and Launches PlaqueX® IV Therapy
  • Leimert Juneteenth Community Celebration Set for Friday, June 19, in Leimert Park Village
  • Advancing High-Potential Nevada Critical Minerals Portfolio as Major Drill Program Nears Assay Results: Glenstar Minerals: Stock Symbol: GSTRF
  • Allstream Energy Partners to Host 6th Executive Networking After 2026 Energy Projects Conference
  • CAPHRA: Australia and Thailand show nicotine prohibition fuels illicit markets
  • Custom Disposables - Wholesale Packaging Solutions for restaurants, food chains, and food distributors
  • STO Foundation Launching June 29, 2026 to Advance the Global Tokenization Industry
  • CCHR Condemns Behavioral Treatment After FDA's Missed Deadline to Ban Shock Device
  • UK Financial Ltd Completes One Of The Most Extensive CoinMarketCap Supply Verification Packages For Maya Preferred PRA (MPRA)
  • TREND Network Announces Miami Based Reality Series "Coming Up Miami" Premiering July 1
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us